Compare Eli Lilly And Co (LLY) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Vanguard Ultra Short Bond ETF — how do they compare? Eli Lilly And Co trades at $1,159.75 (market cap $1.02T), while Vanguard Ultra Short Bond ETF trades at $49.71. The key difference: Eli Lilly And Co pays a 0.6% dividend while Vanguard Ultra Short Bond ETF pays none. Which is the better fit depends on your goals.
| LLY | VUSB | |
|---|---|---|
Market Cap | $1.02T | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $1.24K | $50.03 |
52-Week Low | $625.65 | $49.60 |
Enterprise Value | $1.06T | — |
Dividend Yield | 0.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
VUSB trades at $49.70, up 0.02% on the day, with a bullish technical signal driven by positive momentum indicators. The ETF offers a yield of approximately 4.35%, positioning it as an alternative to money-market funds. Recent dividend payments include $0.18 in April 2026 and $0.17 in May 2026, with another $0.18 scheduled for July 2026.
The outlook for VUSB is supported by potential Federal Reserve rate increases enhancing short-term bond appeal, but risks include credit and duration exposure. The ETF remains a conservative income vehicle amid a non-inverted yield curve, though its technicals show mixed signals with overbought short-term RSI.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
